The Economics of Antibiotic Cement in Total Knee Arthroplasty: Added Cost with No Reduction in Infection Rates.

BACKGROUND: To reduce the substantial clinical and financial burden of periprosthetic joint infection (PJI), some surgeons advocate for the use of antibiotic-loaded bone cement (ALBC) in primary total knee arthroplasty (TKA), although its effectiveness continues to be debated in the literature. The purpose of this study was to determine whether the routine use of ALBC is cost-effective in reducing PJI after primary TKA. METHODS: We retrospectively reviewed a consecutive series of patients undergoing cemented primary TKA at two hospitals within our institution from 2015 to 2017. We compared demographics, comorbidities, costs, and PJI rates between patients receiving ALBC and plain cement. We performed a multivariate regression analysis to determine the independent effect of ALBC on PJI rate. We calculated readmission costs for PJI and reduction in PJI needed to justify the added cost of ALBC. RESULTS: Of 2511 patients, 1077 underwent TKA with ALBC (43%), with no difference in PJI rates (0.56% vs 0.14%, P = .0662) or complications (1.2% vs 1.6%, P = .3968) but higher cement costs ($416 vs $117, P < .0001) and overall procedure costs ($6445 vs $5.968, P < .0001). ALBC had no effect on infection rate (P = .0894). Patients readmitted with PJI had higher overall 90-day episode-of-care claims costs ($49,341 vs $19,032, P < .001). To justify additional costs, ALBC would need to prevent infection in one of every 101 patients. CONCLUSION: Routine use of ALBC in primary TKA is not cost-effective, adding $299 to the cost of episode of care without a reduction in PJI rate. Further study is needed to determine whether select use of ALBC would be justified in high-risk patients.

The Cost Effectiveness of Dilute Betadine Lavage for Infection Prophylaxis in Total Joint Arthroplasty.

BACKGROUND: This article presents a break-even analysis for intraoperative Betadine lavage for the prevention of infection in total hip arthroplasty (THA) and total knee arthroplasty (TKA). METHODS: Protocol costs, baseline infection rates after arthroplasty, and average revision costs were obtained from institutional records and the literature. The break-even analysis determined the absolute risk reduction (ARR) in infection rate required for cost effectiveness. RESULTS: At our institutional price of $2.54, dilute (0.35%) Betadine lavage would be cost effective if initial infection rates of both TKA (1.10%) and THA (1.63%) have an ARR of 0.01%. At a hypothetical lowest cost of $0.50, the ARR is so low as to be immediately cost effective. At a hypothetical high price of $40.00, Betadine is cost effective with ARRs of 0.16% (TKA) and 0.13% (THA). CONCLUSION: Intraoperative Betadine lavage, at typical institutional prices, can be highly cost effective in reducing infection after joint arthroplasty.

Economic impact of treatment for surgical site infections in cases of total knee arthroplasty in a tertiary public hospital in Brazil.

The aim of this study was to estimate the additional cost of treatment of a group of nosocomial infections in a tertiary public hospital. A retrospective observational cohort study was conducted by means of analyzing the medical records of 34 patients with infection after total knee arthroplasty, diagnosed in 2006 and 2007, who met the criteria for nosocomial infection according to the Centers for Disease Control and Prevention. To estimate the direct costs of treatment for these patients, the following data were gathered: length of hospital stay, laboratory tests, imaging examinations, and surgical procedures performed. Their costs were estimated from the minimum values according to the Brazilian Medical Association. The estimated cost of the antibiotics used was also obtained. The total length of stay in the ward was 976 days, at a cost of US$ 18,994.63, and, in the intensive care unit, it was 34 days at a cost of US$ 5,031.37. Forty-two debridement procedures were performed, at a cost of US$ 5,798.06, and 1965 tests (laboratory and imaging) were also performed, at a cost of US$ 15,359.25. US$ 20,845.01 was spent on antibiotics and US$ 1,735.16 on vacuum assisted closure therapy, microsurgical flaps, implant removal, spacer use, and surgical revision. The total additional cost of these cases of hospital infection in 2006 and 2007 was of US$ 91,843.75. Based on that, we demonstrate that the high cost of treatment for hospital infections emphasizes the importance of taking measures to prevent and control hospital infection.

Economic impact of treatment for surgical site infections in cases of total knee arthroplasty in a tertiary public hospital in Brazil

The aim of this study was to estimate the additional cost of treatment of a group of nosocomial infections in a tertiary public hospital. A retrospective observational cohort study was conducted by means of analyzing the medical records of 34 patients with infection after total knee arthroplasty, diagnosed in 2006 and 2007, who met the criteria for nosocomial infection according to the Centers for Disease Control and Prevention. To estimate the direct costs of treatment for these patients, the following data were gathered: length of hospital stay, laboratory tests, imaging examinations, and surgical procedures performed. Their costs were estimated from the minimum values according to the Brazilian Medical Association. The estimated cost of the antibiotics used was also obtained. The total length of stay in the ward was 976 days, at a cost of US$ 18,994.63, and, in the intensive care unit, it was 34 days at a cost of US$ 5,031.37. Forty-two debridement procedures were performed, at a cost of US$ 5,798.06, and 1965 tests (laboratory and imaging) were also performed, at a cost of US$ 15,359.25. US$ 20,845.01 was spent on antibiotics and US$ 1,735.16 on vacuum assisted closure therapy, microsurgical flaps, implant removal, spacer use, and surgical revision. The total additional cost of these cases of hospital infection in 2006 and 2007 was of US$ 91,843.75. Based on that, we demonstrate that the high cost of treatment for hospital infections emphasizes the importance of taking measures to prevent and control hospital infection.

[Cost and outcome of hip's arthroplasty nosocomial infection. Case and control study]. / Costo y desenlace de la infección de artroplastía de cadera. Estudio de caso y control.

Case-control study for evaluation of cost and outcome of nosocomial surgical site infection in primary hip arthroplasty during a period of 5 years. Mean hospitalization time in the orthopedic service was 54 days for cases, and 13 days for control (p<0.05). Mean hospitalization time in Intensive Care Unit (ICU) was 1.1 days for cases. There were 0.83 post primary surgery interventions in cases, and a mean of 2.08 bacteriological cultures in each case. Controls didn't have hospitalizations in the ICU surgical reinterventions nor cultures necessary. The mean cost of infected patients was US $: 6,174.8. Mean cost in controls was US $: 2,354.7. The excess of cost due to infections was US $: 2,354.7 on the average. Outcomes in cases were: normal function 30.8%; moderate or serious sequelae 46.2%; death rate 15, 4%. The measured parameters contributed to raise case costs, and they caused an unsatisfactory outcome for two third of the patients.

Costo y desenlace de la infección de artroplastía de cadera: Estudio de caso y control / Cost and outcome of hip's arthroplasty nosocomial infection: Case and control study

Case-control study for evaluation of cost and outcome of nosocomial surgical site infection in primary hip arthroplasty during a period of 5 years. Mean hospitalization time in the orthopedic service was 54 days for cases, and 13 days for control (p < 0.05). Mean hospitalization time in Intensive Care Unit (ICU) was 1.1 days for cases. There were 0.83 post primary surgery interventions in cases, and a mean of 2.08 bacteriological cultures in each case. Controls didn't have hospitalizations in the ICU surgical reinterventions nor cultures necesary. The mean cost of infected patients was US $: 6,174.8. Mean cost in controls was US $: 2,354.7. The excess of cost due to infections was US $: 2,354.7 on the average. Outcomes in cases were: normal function 30.8 percent; moderate or serious sequelea 46.2 percent; death rate 15, 4 percent. The measured parameters contributed to raise case costs, and they caused an unsatisfactory outcome for two third of the patients.

Estudio de casos y controles efectuado para evaluar el costo y desenlace de la infección del sitio quirúrgico en artroplastía primaria de cadera en cinco años. La media de hospitalización en el Servicio de Traumatología fue de 54 días para los casos y 13 días para los controles (p < 0,05). La media de hospitalización en UCI de los casos fue 1,1 días; hubo 0,83 reintervenciones en los casos y una media de 2,08 cultivos por cada caso. Los controles no tenían hospitalización en UCI, reintervenciones, ni cultivos. El costo promedio de los pacientes infectados fue $ 3.241.800 (US $ 6.174,8). El costo promedio de los controles, alcanzó a $1.236.244 (US $ 2.354,7). El exceso promedio de costo por la infección fue de $ 2.005.556 (US $ 3.820,1). El desenlace fue el siguiente: función normal 30,8 por ciento; secuelas medianas y graves 46,2 por ciento; letalidad 15,4 por ciento. Los factores medidos contribuyeron a encarecer los costos de los casos y produjeron un desenlace insatisfactorio para dos tercios de los pacientes.